2024-518895-30-00
CTIS ↗
RLY-2608, RLY-2608
PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
biotech · PIK3CA Mutation · PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation · RLAY
Relay Therapeutics
Relay Therapeutics trial registry — 7 ClinicalTrials.gov studies with program phase, status, and indication context.
Cambridge, USA HQ
2016 Founded
211 Employees
Public company Type
RLAY · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2016
- Employees
- 211
- Programs
- 6
- Drugs
- 7
- Patents
- 12
Relay Therapeutics clinical trials
Registry index of 7 ClinicalTrials.gov studies linked to Relay Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Relay Therapeutics trial registry — 7 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Relay Therapeutics.
Trial registry
-
- 2025-523083-21-00CTIS ↗
RLY-2608-102
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗